Background
==========

Alzheimer's Disease (AD) is an irreversible progressive disorder characterized by neuronal deterioration that results in loss of cognitive functions, such as memory, communication skills, judgment and reasoning ([@b42-ppa-2-79]). It is a common ([@b23-ppa-2-79]; [@b62-ppa-2-79]) and chronic dementia disorder among elderly people ([@b23-ppa-2-79]), responsible for nearly 70% of all dementias ([@b62-ppa-2-79]). Approximately 4.5 million Americans suffer from AD in the US population, and this number is expected to increase almost 3-fold, to 13.2 million by 2050 ([@b36-ppa-2-79]). The incidence and prevalence of AD increases exponentially between the ages of 65 and 85, approximately doubling every 5 years of age ([@b51-ppa-2-79]). The proportion of new onset cases who are 85 years of age or older is expected to increase from 42% in 1995 to 62% in 2050 ([@b35-ppa-2-79]). In 1995, 7.1% of all deaths in the US were attributable to AD, placing it on a par with cerebrovascular diseases as the third leading cause of death ([@b20-ppa-2-79]). The 1991 estimate of total prevalent cost of the disease was \$67.3 billion (\$173,932 per case), with \$20.6 billion in direct costs (\$47,581 per case) ([@b19-ppa-2-79]). It is a disease with significant economic burden and a high societal impact, with the proportion of older adults increasing in the population ([@b23-ppa-2-79]; [@b36-ppa-2-79]).

The FDA approved 4 cholinesterase inhibitor drug therapies for AD: tacrine, donepezil, galantamine, and rivastigmine, collectively known as acetyl-cholinesterase inhibitors (ChEIs). By inhibiting the breakdown of the enzyme acetylcholine-esterase, these agents are hypothesized to prolong the action of acetylcholine at the postsynaptic receptor by preventing its hydrolysis. Cholinesterase inhibitors are also prescribed for other conditions with cholinergic system dementia such as vascular dementia, Parkinson's disease and multiple sclerosis dementia ([@b41-ppa-2-79]). Though not curative, these medications can slow the progression of AD rather than reverse its progressive decline and have been shown to have a modest beneficial impact on neuropsychiatric outcomes for AD patients ([@b59-ppa-2-79]). The major therapeutic effect on ChEI is to maintain a cognitive function at a stable level during a 6- to 12-month period ([@b27-ppa-2-79], [@b28-ppa-2-79]; [@b29-ppa-2-79], [@b30-ppa-2-79]; [@b31-ppa-2-79]). Additional drug effects are to slow down cognitive deterioration, improve behavioral problems, and increase ability to perform daily living activities ([@b40-ppa-2-79]; [@b27-ppa-2-79], [@b28-ppa-2-79]; [@b29-ppa-2-79], [@b30-ppa-2-79]; [@b31-ppa-2-79]) and improve the patient's mood ([@b34-ppa-2-79]). Recent studies show that the cognitive stabilization effect may be prolonged up to 24 ([@b27-ppa-2-79], [@b28-ppa-2-79]; [@b29-ppa-2-79]; [@b31-ppa-2-79]) to 36 months ([@b30-ppa-2-79]). The four therapies for AD differ by selectivity and specificity for the brain tissue, as well as the ability to interact with other drugs, adverse events on the nervous system and gastrointestinal tract, and hepatotoxicity ([@b62-ppa-2-79]). Tacrine is no longer marketed in the US because of safety precautions ([@b11-ppa-2-79]), and donepezil was the most frequently prescribed ChEI ([@b2-ppa-2-79]; [@b8-ppa-2-79]) at the time of the study.

Persistence to these agents is expected to be suboptimal, as patients are often poorly adherent to chronic medications ([@b4-ppa-2-79]; [@b47-ppa-2-79]). In a number of chronic illnesses, noncompliance to medications has been shown to have a significant negative health impact ([@b44-ppa-2-79]; [@b14-ppa-2-79]; [@b50-ppa-2-79]; [@b9-ppa-2-79]; [@b46-ppa-2-79]; [@b6-ppa-2-79]; [@b49-ppa-2-79]; [@b60-ppa-2-79]), and is estimated to cost the US \$25 billion annually when indirect costs are included ([@b58-ppa-2-79]). Older adults are especially prone to be non-adherent ([@b33-ppa-2-79]) because of susceptibility to adverse events ([@b48-ppa-2-79]; [@b32-ppa-2-79]), deficits in physical dexterity, cognitive skills and memory, and because of the large number of medications they are prescribed ([@b16-ppa-2-79]). Some researchers have found that older patients are generally more likely than younger patients to discontinue their medication ([@b1-ppa-2-79]; [@b5-ppa-2-79]; [@b39-ppa-2-79]). Patients may discontinue ChEI drug therapy as a result of intolerable adverse events, rapid clinical deterioration, or failure to improve, stabilize, or reduce the rate of decline in AD ([@b21-ppa-2-79]). While persistence with specific ChEI medications has not been adequately examined by researchers, switching between different ChEIs has been frequently reported ([@b2-ppa-2-79]; [@b8-ppa-2-79]; [@b18-ppa-2-79]). There is limited information outside the clinical trial setting ([@b45-ppa-2-79]) and results of previous studies examining persistence to ChEIs have been inconsistent ([@b56-ppa-2-79]; [@b45-ppa-2-79]; [@b55-ppa-2-79]) or have included only one type of ChEI ([@b52-ppa-2-79]), thus preventing a comparison.

The objective of this research was to compare rates of persistence between donepezil and other types of ChEIs in usual care settings among a patient population of older adults enrolled in a state Medicaid program. Studies have reported donepezil to have better tolerability than the other ChEIs ([@b53-ppa-2-79]; [@b18-ppa-2-79]; [@b38-ppa-2-79]; [@b61-ppa-2-79]; [@b7-ppa-2-79]). Thus, we assessed persistence with each ChEI medications separately, and overall.

Methods
=======

Study population and design
---------------------------

We conducted a retrospective cohort study among patients enrolled in the Rhode Island Medicaid program between January 1, 2001 and December 31, 2003, and who received at least one dispensing for a ChEI medication. New users of ChEIs were identified by selecting patients receiving an initial prescription for a ChEI medication between July 1, 2001 and December 31, 2003. Those included had no prior dispensing for a ChEI medication in the previous 6 months, and an initial prescription prior to June 30, 2003, such that all patients had at least 6-months of follow-up time. Cases were excluded if they were less than 50 years of age. Information describing demographic and other patient characteristics was made available. Members with greater than a 6-month period (180 days) between refills, or between the last refill and the end of the study period were considered to have discontinued the drug. Switching to other types of cholinesterase inhibitors was assessed separately among those that continued their medication at 6-months and at 1 year.

Independent variables included class of ChEI dispensed (donepezil versus rivastigmine and galantamine), gender, age (age 50--69 years; or age 70 years or greater), race (white versus nonwhite), and care setting (long-term care setting versus community-dwelling). Categorizing age at 70 years was determined after performing an assessment of the parametric form for the age variable.

Descriptive statistics were used to determine the frequencies of various patient characteristics. Survival analysis was used to assess differences in persistence among ChEIs product dispensed, and by the patient characteristics identified above. Kaplan-Meier (KM) curves were independently constructed for each of the predictor variables (class of ChEIs, gender, age, race, setting) and the log-rank statistic was used to evaluate group differences in persistence. Extended Cox proportional hazards models were used to estimate rate ratios (RR) and 95% confidence intervals (CI) for the association between patient characteristics and ChEIs discontinuation. Statistical analyses were carried out using SAS statistical package version 8.01.

Results
=======

A total of 1564 patients met the study's inclusion criteria. Baseline characteristics of the population are presented in [Table 1](#t1-ppa-2-79){ref-type="table"}. The mean age of these patients was 83 years and 76% were female. Most of the patient population were in long-term care (LTC) (86%) and 61% where of white race. Donepezil was the most widely dispensed ChEI accounting for 56.4% of the patients.

[Table 2](#t2-ppa-2-79){ref-type="table"} presents the discontinuation rates at 12 months and 24 months, overall and according to patient characteristics. Overall discontinuation increased with time from 42.7% (95% CI = 39.9--45.5) at 12 months, to 84.8% (95% CI = 82.3--87.3) at 24 months. In univariate analyses, the initial type of dispensed ChEI medication was not associated with discontinuation (p = 0.22). During the first 12 months, males were more likely to discontinue than females (p = 0.04) and whites were less likely to discontinue (p \< 0.0001) than non-white patients.

A small percentage of patients switched ChEI medication type during the study timeframe. Among patients who were started on donepezil and continued the medication for 6 and 12 months, 96% remained on donepezil at 6 months and at 12 months. At 6 months, 1% switched to rivastigmine and 3% switched to galantamine and at 12 months 2% were receiving rivastigmine and 2% were receiving galantamine. Among patients who were started on rivastigmine 92% were still on rivastigmine at 6 months while 4.4% were switched to donepezil and 3.5% to galantamine. At 12 months, 89% were still on rivastigmine, 7.8% were receiving galantamine and 3.2% were receiving donepezil. Finally, among patients who were started on galantamine, 98% remained on galantamine at 6 months, while 1.5% were switched to donepezil and 0.8 % to rivastigmine. At 12 months, 98.7% of these patients were receiving galantamine and 1.3% were receiving rivastigmine. The Medicaid plan had no influence on drug switches, as no restrictions on the use of any particular ChEI medication were in place during the study timeframe.

In multivariate models, persistence rates did not differ among ChEI medication use as assessed during the first 12 months of therapy (RR = 1.002; CI = 0.807--1.243; p = 0.9879). Among those persisting for at least 12 months, users of donepezil were less likely to discontinue during subsequent months as compared with users of the other two ChEIs (RR = 0.70; CI = 0.499--0.983; p \< 0.0397). Overall, patients of white race showed better persistence than of non-white race (RR = 0.549; 95% CI = 0.43--0.82; p = 0.0015). This, however, was based on 66% of the population since 34% had missing values for race. Gender, care setting, and age were not associated with differences in discontinuation. These results are presented in [Table 3](#t3-ppa-2-79){ref-type="table"}. [Figure 1](#f1-ppa-2-79){ref-type="fig"} shows the survival curves for those dispensed donepezil vs other ChEI medications.

Discussion
==========

Our findings suggest that discontinuation rates for ChEIs are high, as previously reported ([@b52-ppa-2-79]; [@b56-ppa-2-79]; [@b45-ppa-2-79]; [@b55-ppa-2-79]), and indicate slightly better persistence with donepezil than other ChEIs beyond 1 year of therapy, adjusting for gender, age, race, and living arrangements (adjusted RR = 0.70; CI = 0.499--0.983; p \< 0.0397). Similar rates of persistence for all ChEI medications for the first 12 months of use were observed (adjusted RR = 1.002; CI = 0.807--1.243; p = 0.9879).

Patients of white race were shown to have better persistence than nonwhites (41% vs 69%), although this finding was based on an analysis of only 66% of the study population, as 34% of individuals had no information describing race in the available data sources. Despite the high rate of missing values for this variable, we believed that it was important to include this covariate in our analysis given the magnitude of difference in the percentages persisting, and because race has also been reported to be among factors associated with noncompliance ([@b3-ppa-2-79]). The smaller percentage of nonwhite cases overall merits further analysis, as it is possible that nonwhite patients were less frequently prescribed ChEI medications. In the multivariate analysis, we did not find persistence rates to differ significantly when assessing by patient age, gender, or by living arrangement. Other researchers evaluating these factors have described inconsistent findings ([@b15-ppa-2-79]; [@b3-ppa-2-79]).

Two studies carried out in primary care health centers in Spain ([@b56-ppa-2-79]; [@b55-ppa-2-79]) also demonstrated better persistence of donepezil than rivastigmine and galantamine. [@b45-ppa-2-79] found similar rates of persistence between rivastgmine and donepezil in a retrospective community-based study. This research, however, looked at 6 months of medication persistence and did not evaluate persistence rates after 1 year. Thus, our results are consistent since we found no significant difference in persistence prior to 1 year of therapy. Furthermore, [@b45-ppa-2-79] recognized that the limited sample size of rivastgmine patients might have limited the authors' ability to detect differences in persistence.

Leading reasons for discontinuation of ChEI therapy include patient or physician-perceived ineffectiveness, intolerance of side effects, or an inconvenient dosing schedule ([@b45-ppa-2-79]). Reported side effects include nausea, vomiting, and diarrhea ([@b54-ppa-2-79]; [@b53-ppa-2-79]; [@b18-ppa-2-79]; [@b45-ppa-2-79]). Donepezil has been reported to have better tolerability and a milder side effect profile than other ChEIs ([@b53-ppa-2-79]; [@b18-ppa-2-79]; [@b38-ppa-2-79]; [@b61-ppa-2-79]) which might explain the observed difference in persistency rates beyond 1 year. This, nonetheless, does not explain why similar persistency rates were observed prior to 1 year, since side effects are expected to start before 1 year. Additionally, based on comparison of persistence rates, our results do not support reports that rivastigmine provides a higher magnitude of benefits than donepezil ([@b53-ppa-2-79]; [@b18-ppa-2-79]; [@b38-ppa-2-79]; [@b61-ppa-2-79]).

The cost-effectiveness of ChEI therapy has been questioned, particularly given the high direct cost for these medications ([@b12-ppa-2-79], [@b13-ppa-2-79]; [@b22-ppa-2-79]; [@b17-ppa-2-79]; [@b43-ppa-2-79]). Outcome evaluations should also consider the quality of life of the patient and of care givers, and the importance of developing a quality of life instrument for both ([@b43-ppa-2-79]). It is difficult to quantify benefits as reported in the literature since improvements in tests such as ADAS-cog (Alzheimer's Disease Assessment Scale cognitive subscale) may not be reflected in changes of daily life ([@b12-ppa-2-79]).

Because there is currently no cure for AD, one cannot expect the initial cognitive improvement observed in the first few months of therapy to be sustained indefinitely. However, one should expect that some patients who are treated early and persistently with AD medications will show less evidence of behavioral and cognitive deterioration over a period of time than one would expect in the absence of pharmacotherapy, and less decline over the long term ([@b25-ppa-2-79]). By reducing cognitive and functional declines over time, long-term therapy may enable patients to stay at home longer and decrease the burden faced by patients, caregivers, and society ([@b24-ppa-2-79]). [@b24-ppa-2-79] reported that taking donepezil for 9--12 months delays nursing home placement. [@b37-ppa-2-79] demonstrated lower costs for 204 AD patients in a large Medicare managed care plan on donepezil compared with 204 patients not receiving therapy with matched characteristics, where annual costs of prescriptions and medical services were \$3,891 lower for the study group. Longer term therapy (≥270 days) also achieved lower costs compared to shorter term therapy. In our study population, 686 (57.3%) patients remained on therapy for 12 months, a figure that may represent a cost-savings considering the potential outcomes described above.

Several limitations to this study can be described. Clinical data regarding diagnosis, doses used, and exact reason for discontinuation were lacking. Prescription dispensing data were used to evaluate persistence, and filling the prescription does not ensure that the drug was actually consumed. Nonetheless, refill data are considered more objective than self-report which can overestimate compliance ([@b10-ppa-2-79]), and is a useful tool to assess the drug use in population-based studies ([@b57-ppa-2-79]). We could not account for use of samples or hospitalizations during a follow-up period. However, we believe that our criterion of 6 months without a prescription being dispensed to be classified as nonpersistent mitigates the potential influence of these factors because it would be difficult to obtain drug samples that cover such a long period of time and it is a long period for a continuous hospitalization. Severity of AD was not assessed, but including newly treated patients in the study addresses this concern to some degree, and these medications were approved for only use in mild to moderate disease as of the time of the study. We were unable to control for potential confounders pertaining to patient co-morbidities, and 34% of the population had missing values for race. Additionally, as all the patients were enrolled in a Medicaid program, they are expected to be of lower incomes and to have no co-payments for medications. This, however, might limit generalizability of the results to other populations.

While the improvements gained with the use of ChEI medications may be small or modest, sustained benefits of therapy can be realized only by patients who persist with therapy. Yet our results indicate that persistence rates with these medications are quite low. Persistence rates were higher for donepezil users compared with those who received other ChEI medication beyond 12 months, yet given the marginal difference and the limitations of our data source, we are unable to conclude that this difference suggests superiority of donepezil.

Conclusions
===========

We found similar persistence rates for each of the three available ChEI medications, with a 42% rate of persistence at 12 months, and those dispensed donepezil were slightly more likely to persist at 24 months. While we were not able to ascertain if discontinuation was due to lack of efficacy or lack of tolerability, our analyses revealed that nearly half of patients failed to persist with ChEI therapy for at least 12 months. Our findings underscore the limitations of the ChEI medications and the urgent need for effective and tolerable therapeutic options for patients having dementia. From a drug policy perceptive, the consideration of the utility of ChEI medications should include both results from clinical trials and insights from observational studies such as ours, which reveal that for many patients ChEI medications cannot be relied upon to provide longer-term benefit in managing dementia. Reports describing measures of therapy persistence can be important to caregivers and patients in forming expectations for pharmacotherapy.
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###### 

Characteristics of new users of cholinesterase inhibitor (ChEI) medications (n = 1564)

  Characteristic                          n (%)
  ---------------------- ---------------- --------------
  Gender                 Females          1190 (76.1%)
                         Males            374 (23.9%)
  Age (years)            Mean 83.1        
                         SD 9.1           
                         ≥70              1435 (91.8%)
                         50--69           129 (8.2%)
  Race                   White            956 (61.1%)
                         None-white       75 (4.8%)
                         Missing          533 (34.1%)
  Initial type of ChEI   Donepezil        882 (56.4%)
  medication dispensed   Rivastigmine     317 (20.3%)
                         Galantamine      365 (23.3%)
  Setting                Long-term care   1340 (85.7%)
                         Community        224 (14.3%)

**Abbreviation:** SD, standard deviation.

###### 

Discontinuation rates of cholinesterase inhibitors medications at 12 and 24 months (n = 1564)

  Variable                               Discontinued by 12 months n   \%      CI               Discontinued by 24 months n   \%      Log rank probability CI
  -------------------------------------- ----------------------------- ------- ---------------- ----------------------------- ------- ---------------------------------------------------
  Total population                       513/1199                      42.7%   (39.9%--45.5%)   692/816                       84.8%   (82.3%--87.3%)
  Initial type of medication dispensed                                                                                                0.2218
   Donepezil                             279/673                       41.4%   (37.7%--45.1%)   373/442                       84.4%   (81.0%--87.8%)
   Rivastigmine                          115/250                       46.0%   (39.8%--52.2%)   158/184                       85.9%   (80.9%--90.9%)
   Galantamine                           119/277                       43.0%   (37.1%--48.8%)   162/190                       85.3%   (80.3%--90.3%)
  Gender                                                                                                                              0.0405[\*](#tfn2-ppa-2-79){ref-type="table-fn"}
   Female                                373/919                       40.6%   (37.4%--43.7%)   515/615                       83.7%   (80.8%--86.6%)
   Male                                  140/282                       49.6%   (43.8%--55.4%)   177/201                       88.1%   (83.6%--92.6%)
  Age                                                                                                                                 0.1475
   50--69                                459/1102                      41.7%   (38.7%--44.5%)   629/740                       85.0%   (82.4%--87.5%)
   \< 70                                 54/100                        54.0%   (44.2%--63.8%)   63/75                         84.0%   (75.7%--92.3%)
  Race                                                                                                                                \<0.0001[\*](#tfn2-ppa-2-79){ref-type="table-fn"}
   White                                 303/742                       40.8%   (37.3%--44.3%)   417/496                       84.1%   (80.9%--87.3%)
   Non-white                             42/61                         68.9%   (57.3%--80.5%)   47/48                         97.9%   (93.8%--101.9%)
  Setting                                                                                                                             0.3202
   Long-term care                        430/1037                      41.5%   (38.5%--44.5%)   594/707                       84.0%   (81.3%--86.7%)
   Community                             83/165                        50.3%   (42.7%--57.9%)   98/109                        89.9%   (84.2%--95.6%)

Significant result p \< 0.05.

**Abbreviation:** CI, confidence interval.

###### 

Adjusted associations between patient characteristics and discontinuation of cholinesterase inhibitors (ChEI) medications (n = 1564)

  Variable                                                                 Adjusted rate ratio                              95% CI
  ------------------------------------------------------------------------ ------------------------------------------------ --------------
  Initial type of ChEI medication dispensed, persistence up to 365 days                                                     
   Galantamine or rivastigmine                                             1.0 (reference)                                  
   Donepezil                                                               1.002                                            0.807--1.243
  Initial type of ChEI medication dispensed, persistence beyond 365 days                                                    
   Galantamine or rivastigmine                                             1.0 (reference)                                  
   Donepezil                                                               0.700[\*](#tfn4-ppa-2-79){ref-type="table-fn"}   0.499--0.983
  Gender                                                                                                                    
   Female                                                                  1.0 (reference)                                  
   Male                                                                    1.082                                            0.877--1.335
  Age                                                                                                                       
   50--69 years                                                            1.0 (reference)                                  
   ≥ 70 years                                                              0.898                                            0.672--1.202
  Race                                                                                                                      
   Non-white                                                               1.0 (reference)                                  
   White                                                                   0.594[\*](#tfn4-ppa-2-79){ref-type="table-fn"}   0.430--0.820
  Setting                                                                                                                   
   Community                                                               1.0 (reference)                                  
   Long term care                                                          0.873                                            0.672--1.135

Significant result.

**Abbreviation:** CI, confidence interval.
